Posted by Michael Wonder on 16 Jun 2026
Halia Therapeutics receives FDA fast track designation for ofirnoflast (HT-6184) in lower-risk myelodysplastic syndromes
15 June 2026 - Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026
Halia Therapeutics today announced that the US FDA has granted fast track designation to ofirnoflast (HT-6184) for the treatment of adult patients with lower risk myelodysplastic syndromes.
